Zoledronic acid
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
 | |
 | |
| Clinical data | |
|---|---|
| [[Regulation of therapeutic goods |Template:Engvar data]] |
|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 22% |
| Metabolism | Nil |
| Elimination half-life | 146 hours |
| Excretion | Renal (partial) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C5H10N2O7P2 |
| Molar mass | 272.09 g/mol |
|
WikiDoc Resources for Zoledronic acid |
|
Articles |
|---|
|
Most recent articles on Zoledronic acid Most cited articles on Zoledronic acid |
|
Media |
|
Powerpoint slides on Zoledronic acid |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Zoledronic acid at Clinical Trials.gov Trial results on Zoledronic acid Clinical Trials on Zoledronic acid at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Zoledronic acid NICE Guidance on Zoledronic acid
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Zoledronic acid Discussion groups on Zoledronic acid Patient Handouts on Zoledronic acid Directions to Hospitals Treating Zoledronic acid Risk calculators and risk factors for Zoledronic acid
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Zoledronic acid |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Zoledronate (INN: zoledronic acid, marketed by Novartis under the trade names Zometa and Reclast) is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases.
An annual dose of zoledrinic acid may also prevent recurring fractures in patients with a previous hip fracture. [1]
Reclast is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.
Administration
The standard dose for zoledronate is 4 mg to be infused intravenously over 15 min every 3-4 weeks in cancer patients. For Reclast a single dose of 5 mg is used for the treatment of Paget's disease.
Zoledronate has been approved as a once-yearly 5 mg infusion for treatment of osteoporosis and shown significant benefits versus placebo over three years, with a reduced number of vertebral fractures and improved markers of bone density.[2] [3]
Side effects
Side effects can include fatigue, anemia, muscle aches, fever, and/or swelling in the feet or legs. Flu-like symptoms are commonly experienced after the first zoledronate infusion, although not subsequent infusions, and are thought to occur because of its potential to activate human γδ T cells.
Zoledronate is rapidly processed via the kidneys; consequently its administration is not recommended for patients with reduced renal function or kidney disease.
A rare complication that has been recently observed in cancer patients being treated with bisphosphonates is osteonecrosis of the jaw. This has mainly been seen in patients with multiple myeloma treated with zoledronate who have had dental extractions.[4]
Contraindications
- Poor renal function (e.g. creatinine>3 mg/dL)
- Pregnancy
- Paralysis
References
- ↑ Lyles K; et al. (2007). "Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture". N. Engl. J. Med. PMID 17878149.
- ↑ Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ (2002). "Intravenous zoledronic acid in postmenopausal women with low bone mineral density". N. Engl. J. Med. 346 (9): 653–61. PMID 11870242.
- ↑ Black et al.. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. NEJM 2007;356;18;1809-1822. Abstract
- ↑ Durie BG, Katz M, Crowley J (2005). "Osteonecrosis of the jaw and bisphosphonates". N. Engl. J. Med. 353 (1): 99–102, discussion 99-102. PMID 16000365.
External links
- http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=246
- http://www.multiplemyeloma.org/treatments/3.06.html
- http://www.us.zometa.com/info/index.jsp
- http://www.zometa.com/index.jsp
- http://www.reclast.com/
- Pages with script errors
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drug has EMA link
- Articles containing unverified chemical infoboxes
- Bisphosphonates
- Imidazoles
- Endocrinology